Editor’s Choice: Approvals and Disappointments in Rare Research News

Happy Thursday Everyone!

We hope everyone’s spring is off to a good start! This week, we’re highlighting four articles about research updates. We have news pertaining to Methylmalonic Acidemia patients and families followed by an update on Hemophilia A treatment research. Next, we have news on a trial discontinuation as well as a Multiple Myeloma approval in England.

Sit back and enjoy this week’s Editor’s Choice.

[one_half]

 

[/one_half] [one_half_last]

NIH Works With Patients and Families on Methylmalonic Acidemia Research

The NIH is taking steps to involve the communities affected by this rare disease.

[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients

Research shows this treatment could help Hemophilia A patients prevent bleeds before they happen.
[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

Phase III Ovarian Cancer Clinical Trial to be Discontinued

Ovarian cancer treatment development experiences a setback.

[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

New Combination Therapy for Multiple Myeloma Approved in England

Our friends across the pond have new treatment options for Multiple Myeloma.

[one_half]

Do you have a rare disease experience of your own? Share with us here.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email